Samer A. Al’Hadidi, MD, discusses social determinants and resources that can help patients receive chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma.
The University of Arkansas for Medical Sciences said Monday it has received a five-year, $2.9 million research grant from the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback